ADDRESSING PATIENT NEEDS WITH GLP-1 RA THERAPIES: CHALLENGES FOR DRUG DELIVERY 

Published: 21/05/2026

 

Every day, headlines highlight the growing impact of diabetes and obesity. Together, these conditions—now often referred to as diabesity—represent one of the most pressing global health challenges of our time. With over one billion people affected by obesity worldwide and diabetes cases continuing to rise, healthcare systems are under increasing pressure to deliver effective, scalable, and patient-friendly solutions.

At the heart of this challenge lies a simple truth: patients are not all the same. Their needs vary by geography, lifestyle, economic context, and treatment experience. Addressing this diversity requires more than innovative drugs—it demands smart, adaptable drug delivery solutions designed around real patient lives.

Designing for real-world diversity

From the United States to Europe to emerging markets such as India, treatment approaches differ significantly. 

Patients may require: 

  • High volume or low-volume injections 
  • Fixed or adjustable dosing
  • Disposable or reusable devices
  • Cost-sensitive or premium solutions

A one-size-fits-all approach is no longer viable. Instead, success depends on flexibility, usability, and accessibility—delivered through thoughtfully engineered platforms...

To read the full article: https://www.nemera.net/wp-content/uploads/2026/05/ADDRESSING-PATIENT-NEEDS.pdf

About Nemera

As a world-leading drug delivery device solutions and combination product services partner, Nemera’s purpose of putting patients first enables the design and manufacture of devices that maximize treatment efficacy.
Nemera is committed to the highest quality standards, from early device strategy to state-of-the-art manufacturing.
Agile and open-minded, Nemera works closely with customers to ensure the success of their combination products.

About the Author

Cécile Gross

Cécile Gross is Marketing Global Category Manager at Nemera, focusing on parenteral devices. She oversees the product portfolio strategy, development and lifecycle for safety system, pen injector and on-body injector platforms. She has more than two decades of experience in the medical device industry, marketing business-to-business technological products and implementing product lifecycle management for various kinds of devices. Ms Gross holds a degree in International Business and completed her initial training with a Master’s degree in Marketing and Management in the Healthcare Industry at IMIS Institute, Lyon, France.

Latest News

See All News